A recent study integrating clinical samples, cellular models, and xenograft mouse experiments revealed that METTL3 directly targets DLG2 mRNA via m6A modification, significantly shortening its half-life and leading to consistently low DLG2 expression in CC tissues and cell lines (122). Here, METTL3 is linked to cholangiocarcinoma.